OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

被引：48

作者：

Becker, Matthijs L. ^{[1
,2
]}

Visser, Loes E. ^{[1
,2
]}

van Schaik, Ron H. N. ^{[3
,4
]}

Hofman, Albert ^{[1
,5
]}

Uitterlinden, Andre G. ^{[1
,5
,6
]}

Stricker, Bruno H. Ch. ^{[1
,5
,6
,7
]}

机构：

[1] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands

[2] Erasmus MC, Hosp Pharm, NL-3000 CA Rotterdam, Netherlands

[3] Erasmus MC, Dept Clin Chem, NL-3000 CA Rotterdam, Netherlands

[4] STAR Med Diagnost Ctr, Rotterdam, Netherlands

[5] Netherlands Consortium Healthy Aging, Leiden, Netherlands

[6] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands

[7] Inspectorate Hlth Care, Drug Safety Unit, The Hague, Netherlands

来源：

NEUROGENETICS | 2011年 / 12卷 / 01期

关键词：

Organic Cation Transporter 1; Anti-Parkinson Agents; Pharmacogenetics; Pharmacoepidemiology; ORGANIC CATION TRANSPORTERS; DOPAMINE-D-2; AGONIST; PRAMIPEXOLE; KIDNEY; CELLS;

D O I：

10.1007/s10048-010-0254-5

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we associated this polymorphism with higher prescribed doses of all anti-Parkinsonian drugs. Between the first and fifth prescriptions for levodopa, for each minor rs622342 C allele, the prescribed doses were 0.34 defined daily dose higher (95% CI 0.064, 0.62; p = 0.017). The mortality ratio after start of levodopa therapy was 1.47 times higher (95% CI 1.01, 2.13; p = 0.045).

引用

页码：79 / 82

页数：4

共 12 条

[1] Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus [J].

Becker, M. L. ;

Visser, L. E. ;

van Schaik, R. H. N. ;

Hofman, A. ;

Uitterlinden, A. G. ;

Stricker, B. H. C. .

PHARMACOGENOMICS JOURNAL, 2009, 9 (04) :242-247

[2] Catecholamine transport by the organic cation transporter type 1 (OCT1) [J].

Breidert, T ;

Spitzenberger, F ;

Gründemann, D ;

Schömig, E .

BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (01) :218-224

[3] The International HapMap Project [J].

Gibbs, RA ;

Belmont, JW ;

Hardenbol, P ;

Willis, TD ;

Yu, FL ;

Yang, HM ;

Ch'ang, LY ;

Huang, W ;

Liu, B ;

Shen, Y ;

Tam, PKH ;

Tsui, LC ;

Waye, MMY ;

Wong, JTF ;

Zeng, CQ ;

Zhang, QR ;

Chee, MS ;

Galver, LM ;

Kruglyak, S ;

Murray, SS ;

Oliphant, AR ;

Montpetit, A ;

Hudson, TJ ;

Chagnon, F ;

Ferretti, V ;

Leboeuf, M ;

Phillips, MS ;

Verner, A ;

Kwok, PY ;

Duan, SH ;

Lind, DL ;

Miller, RD ;

Rice, JP ;

Saccone, NL ;

Taillon-Miller, P ;

Xiao, M ;

Nakamura, Y ;

Sekine, A ;

Sorimachi, K ;

Tanaka, T ;

Tanaka, Y ;

Tsunoda, T ;

Yoshino, E ;

Bentley, DR ;

Deloukas, P ;

Hunt, S ;

Powell, D ;

Altshuler, D ;

Gabriel, SB ;

Qiu, RZ .

NATURE, 2003, 426 (6968) :789-796

[4] Opossum kidney cells take up L-dopa through an organic cation potential-dependent and proton-independent transporter [J].

Gomes, P ;

Serrao, MP ;

VieiraCoelho, MA ;

SoaresDaSilva, P .

CELL BIOLOGY INTERNATIONAL, 1997, 21 (04) :249-255

[5] The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules [J].

Goralski, KB ;

Lou, GL ;

Prowse, MT ;

Gorboulev, V ;

Volk, C ;

Koepsell, H ;

Sitar, DS .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :959-968

[6] The Rotterdam Study: 2010 objectives and design update [J].

Hofman, Albert ;

Breteler, Monique M. B. ;

Duijn, Cornelia M. van ;

Janssen, Harry L. A. ;

Krestin, Gabriel P. ;

Kuipers, Ernst J. ;

Stricker, Bruno H. Ch. ;

Tiemeier, Henning ;

Uitterlinden, Andre G. ;

Vingerling, Johannes R. ;

Witteman, Jacqueline C. M. .

EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2009, 24 (09) :553-572

[7] Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney [J].

Ishiguro, N ;

Saito, A ;

Yokoyama, K ;

Morikawa, M ;

Igarashi, T ;

Tamai, I .

DRUG METABOLISM AND DISPOSITION, 2005, 33 (04) :495-499

[8] Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3) [J].

Jonker, JW ;

Schinkel, AH .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (01) :2-9

[9] Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications [J].

Koepsell, Hermann ;

Lips, Katrin ;

Volk, Christopher .

PHARMACEUTICAL RESEARCH, 2007, 24 (07) :1227-1251

[10] Apical uptake of organic cations by human intestinal Caco-2 cells:: putative involvement of ASF transporters [J].

Martel, F ;

Gründemann, D ;

Calhau, C ;

Schömig, E .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 363 (01) :40-49

← 1 2 →